Literature DB >> 22544328

Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.

Francesca Ricci1, Sergio Bernasconi, Patrizia Perego, Monica Ganzinelli, Giorgio Russo, Francesca Bono, Costantino Mangioni, Robert Fruscio, Mario Signorelli, Massimo Broggini, Giovanna Damia.   

Abstract

Solid tumors appear to contain a subpopulation of cells (tumor-initiating cells, TICs) that not only drives and sustains tumor growth, but is possibly responsible for recurrence. We isolated, after enzymatic digestion of primary ovarian carcinoma samples, a subpopulation of cells propagating as non-adherent spheres in medium suitable for tumor stem cells. These cells were able to self-renew in vitro, as suggested by PKH-26 staining studies, were tumorigenic and acquired an epithelial morphology when grown in FBS-supplemented medium, losing their tumorigenic potential. Interestingly, the tumorigenic potential of PKH-26 (high) - and PKH-26 (neg) -sorted cells was similar. These TIC-enriched cultures showed higher levels of genes involved in stemness than differentiated cells derived from them and were more resistant to the cytotoxic effects of some drugs but equally sensitive to others. The higher level of ABCG2 efflux pump could explain increased resistance to taxol and VP16, and higher levels of genes involved in nucleotide excision repair partially explain the resistance to cisplatin. These cells express mesenchymal markers, and epithelial transition could be induced when cultured in differentiating conditions, with a loss of invasive potential. These data suggest that ovarian cancer is a stem cell disease and should help elucidate the role of these cells in the aggressive phenotype of this tumor and find new therapeutic strategies to reduce resistance to current chemotherapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544328     DOI: 10.4161/cc.20308

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  17 in total

1.  Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.

Authors:  Jonathan D Boone; Rebecca C Arend; Bobbi E Johnston; Sara J Cooper; Scott A Gilchrist; Denise K Oelschlager; William E Grizzle; Gerald McGwin; Abhishek Gangrade; J Michael Straughn; Donald J Buchsbaum
Journal:  Lab Invest       Date:  2015-12-14       Impact factor: 5.662

2.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

3.  ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Authors:  Francesca Ricci; Sergio Bernasconi; Luca Porcu; Eugenio Erba; Nicolò Panini; Robert Fruscio; Federica Sina; Valter Torri; Massimo Broggini; Giovanna Damia
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

4.  Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer.

Authors:  Francesca Ricci; Federica Guffanti; Roberta Affatato; Laura Brunelli; Pastorelli Roberta; Robert Fruscio; Patrizia Perego; Maria Rosa Bani; Giovanna Chiorino; Andrea Rinaldi; Francesco Bertoni; Maddalena Fratelli; Giovanna Damia
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 5.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

6.  YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.

Authors:  Yan Xia; Yin-Li Zhang; Chao Yu; Ting Chang; Heng-Yu Fan
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

7.  Selenium-enriched polysaccharides from Pyracantha fortuneana (Se-PFPs) inhibit the growth and invasive potential of ovarian cancer cells through inhibiting β-catenin signaling.

Authors:  Qianling Sun; Mengmeng Dong; Zhihui Wang; Changdong Wang; Deqiao Sheng; Zhihong Li; Debin Huang; Chengfu Yuan
Journal:  Oncotarget       Date:  2016-05-10

8.  Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer.

Authors:  Irma Virant-Klun; Martin Stimpfel
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

Review 9.  Regulation of ovarian cancer stem cells or tumor-initiating cells.

Authors:  Mi Jeong Kwon; Young Kee Shin
Journal:  Int J Mol Sci       Date:  2013-03-25       Impact factor: 5.923

10.  Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.

Authors:  Irma Virant-Klun; Natasa Kenda-Suster; Spela Smrkolj
Journal:  J Ovarian Res       Date:  2016-03-03       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.